NEW YORK, April 11, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Questcor
Pharmaceuticals, Inc. (NASDAQ: QCOR), Jazz Pharmaceuticals plc
(NASDAQ: JAZZ), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Private wealth members
receive these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
Regeneron Pharmaceuticals, Inc. Analyst
Notes
On April 1, 2014, Regeneron
Pharmaceuticals, Inc. (Regeneron), together with Sanofi, announced
that the Phase 2 study with alirocumab, an antibody targeting
proprotein convertase subtilisin/kexin type 9 (PCSK9) yielded
positive results after it demonstrated a bad cholesterol percentage
reduction in patients randomized to receive one of three doses of
the said antibody every other week combined with statin therapy, as
compared with patients receiving placebo. According to the Company,
in week 12, the mean percentage reduction in
lipoprotein-cholesterol (LDL-C) receiving alirocumab in 50mg, 75mg,
and 150mg doses every other week was 55%, 62%, and 72%,
respectively, compared with 3% mean reduction rate in the placebo
group. Commenting on the results, George D.
Yancopoulos, M.D., Ph.D., Chief Scientific Officer and
Laboratories President, Regeneron, said, "Hypercholesterolemia is a
growing problem in Japan and many
patients are poorly-controlled on statins. The results from this
trial support the efficacy and safety of alirocumab at a range of
doses in Japanese patients." The full analyst notes on Regeneron
Pharmaceuticals, Inc. will be available to download free of charge
at:
http://www.AnalystsReview.com/04112014/REGN/report.pdf
--
Questcor Pharmaceuticals, Inc. Analyst Notes
On March 20, 2014, Questcor
Pharmaceuticals, Inc. (Questcor) announced that it is contributing
$175,000 to Child Neurology Society
(CNS) and Child Neurology Foundation (CNF) to fund the Philip R.
Dodge Young Investigator Award, totalling the Company's commitment
to the Dodge award to $250,000.
Steve Cartt, CEO, Questcor, said,
"Questcor's support of the child neurology community is unwavering
and we are very pleased to support the Philip R. Dodge Young
Investigator Award. Supporting this cornerstone program of the
Child Neurology Society will help encourage young scientists to
focus their research efforts on initiatives to advance the
understanding and treatment of pediatric neurological disorders.
Our hope is that these efforts will help pave the way for new and
more effective treatments for the many children impacted by these
disorders." The full analyst notes on Questcor Pharmaceuticals,
Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04112014/QCOR/report.pdf
--
Jazz Pharmaceuticals plc Analyst
Notes
On March 31, 2014, Jazz
Pharmaceuticals plc (Jazz), together with Gentium S.p.A., announced
the European commercial launching of Defitelio (defibrotide), the
first licensed product designed to treat sever hepatic
veno-occlusive disease (severe VOD) in patients over one month of
age undergoing haematopoietic stem cell transplantation (HSCT)
therapy. According to the Company, severe VOD is a complex and
unpredictable disease affecting in over 80% of European patients.
Jazz stated that the efficacy of Defitelio to treat sVOD in HSCT
patients resulted from a successful phase 3 trial that provided a
significant increase of 52% survival rates among patients treated
for 100 days compared with patients in the historical control
group. The Company informed that Defitelio will be launched in 27
additional European countries starting in 2014 until next year. The
full analyst notes on Jazz Pharmaceuticals plc are available to
download free of charge at:
http://www.AnalystsReview.com/04112014/JAZZ/report.pdf
--
Ariad Pharmaceuticals, Inc. Analyst
Notes
On March 24, 2014, Ariad
Pharmaceuticals, Inc. (Ariad) announced the initiation of the
pivotal Phase 2 trial of AP26113 in patients with locally advanced
or metastatic non-small cell lung cancer (NSCLC) previously treated
with crizotinib. Ariad informed that ALK in Lung Cancer Trial of
AP26113 (ALTA) is designed to determine the safety and efficacy of
AP26113 in patients who tested positive for anaplastic lymphoma
kinase (ALK+) oncogene. According to the Company, the ALTA trial's
primary goal is to achieve an objective response rate (ORR)
measured by RECIST criteria, while recording time to response,
duration of response, disease control rate, progression-free
survival, overall survival, safety and tolerability comes
secondary. Ariad added that full patient enrolment is expected in
Q3 2015 and the Company expects to report first data from the trial
in during the medical meeting in 2015. The full analyst notes on
Ariad Pharmaceuticals, Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/04112014/ARIA/report.pdf
--
BioMarin Pharmaceutical Inc. Analyst
Notes
On March 21, 2014, BioMarin
Pharmaceutical Inc. (BioMarin) announced the appointment of
Dennis J. Slamon, M.D. Ph.D.,
Clinical/Translational Research Director Revlon /UCLA Women's
Cancer Research Program Director, to the Company's Board of
Directors. According to the Company, Dr. Slamon won nearly two
dozen national and international research awards honoring his
scientific endeavors, and has mostly changed the way cancer is
treated. Commenting on the appointment, Jean-Jacques Bienaimé, CEO,
BioMarin, said, "I am delighted that Dr. Slamon will be joining
BioMarin's board. His experience in translating discovery into
medicines is aligned with our mission to treat patients with unmet
medical needs based on a specific knowledge of the molecular basis
of their disease. As BioMarin builds its pipeline of early and late
stage therapies, Dr. Slamon's support will help us achieve success
in the clinic." The full analyst notes on BioMarin Pharmaceutical
Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04112014/BMRN/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review